loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Drug Master Files (DMF) for 23013 Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Chattem Chemicals, Inc

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Aspen API. More than just an API.

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 Chattem Chemicals, Inc (1)

    filter

    01 FENTANYL CITRATE USP (1)

    filter

    01 U.S.A (1)

    filter

    01 Active (1)

    filter

    01 Complete (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    CHATTEM CHEMICALS INC

    Contact Supplier
    • FDA
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    FENTANYL CITRATE USP

    PDF Supplier PDF
    URL Supplier Web Content
    23013
    Active
    2009-10-26
    Complete
    2014-03-15
    2013-09-13
    II
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for Drug Master Files (DMF) for 23013 of Chattem Chemicals Inc

    Looking for Drug Master Files (DMF) for 23013 of Chattem Chemicals Inc 1

    20

    Chattem Chemicals Inc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA.

    One of their notable products is FENTANYL CITRATE USP, with a corresponding US DMF Number 23013.

    Remarkably, this DMF maintains an Active status since its submission on October 26, 2009, highlighting commitment to regulatory compliance.

    Their GDUFA DMF Review was successfully complete, with a review date of March 15, 2014, and payment made on September 13, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II

    Post Enquiry
    POST ENQUIRY